The First New Drug Class in Over a Decade
The FDA approved Jascayd (nerandomilast) tablets for progressive pulmonary fibrosis in adults. September 2026. First and only preferential phosphodiesterase 4B inhibitor with immunomodulatory and antifibrotic effects approved for this indication. First new antifibrotic drug class in over a decade. I have pulmonary fibrosis. Diagnosed July 2024: interstitial lung disease, bronchiectasis, COPD, CRPD, asthma. Prognosis was 6 months to 2 years. That was July 2024. I'm still here, 26 months later. So when a new drug class clears FDA approval, I pay attention. WHAT IT DOES Nerandomilast is a PDE4B inhibitor. Phosphodiesterase 4B sits inside immune cells and inflammatory cells – inhibiting it reduces inflammation and slows fibrotic scarring in lung tissue. The pivotal Phase III FIBRONEER-ILD trial demonstrated nerandomilast effectively slowed lung function decline in progressive pulmonary fibrosis, with similar permanent discontinuation rates to placebo. That second part matters: the drug...